Madrigal Pharmaceuticals Stock Filter Stocks by Fundamentals
| MDGL Stock | USD 313.40 17.54 5.30% |
Fundamental analysis of Madrigal Pharmaceuticals allows traders to better anticipate movements in Madrigal Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Madrigal | Shares Owned by Institutions | Build AI portfolio with Madrigal Stock |
Madrigal Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Madrigal Pharmaceuticals from analyzing Madrigal Pharmaceuticals' financial statements. These drivers represent accounts that assess Madrigal Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Madrigal Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.7B | 1.4B | 5.0B | 4.3B | 6.6B | 6.9B | |
| Enterprise Value | 1.7B | 1.4B | 4.7B | 4.3B | 6.6B | 6.9B |
Madrigal Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Madrigal Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Madrigal Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Madrigal Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.| Shares | Holocene Advisors, Lp | 2025-03-31 | 390.5 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 384.8 K | William Blair Investment Management, Llc | 2025-03-31 | 353.2 K | Ubs Group Ag | 2025-03-31 | 321.5 K | Woodline Partners Lp | 2025-03-31 | 317.4 K | Bank Of America Corp | 2025-03-31 | 246 K | Hood River Capital Management Llc | 2025-03-31 | 244 K | Pictet Asset Manangement Sa | 2025-03-31 | 207 K | Adage Capital Partners Gp Llc | 2025-03-31 | 191.6 K | Hhg Plc | 2025-03-31 | 2.2 M | Paulson & Company Inc | 2025-03-31 | 2.1 M |
Madrigal Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.23) % | ||||
| Operating Margin | (0.58) % | ||||
| Current Valuation | 6.24 B | ||||
| Shares Outstanding | 22.2 M | ||||
| Shares Owned By Insiders | 7.73 % | ||||
| Shares Owned By Institutions | 92.27 % | ||||
| Number Of Shares Shorted | 3.97 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 9.79 X | ||||
| Price To Sales | 21.92 X | ||||
| Revenue | 180.13 M | ||||
| Gross Profit | 306.64 M | ||||
| EBITDA | (450.12 M) | ||||
| Net Income | (465.89 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 119.57 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 32.03 X | ||||
| Cash Flow From Operations | (455.57 M) | ||||
| Short Ratio | 12.57 X | ||||
| Earnings Per Share | (17.83) X | ||||
| Target Price | 425.0 | ||||
| Number Of Employees | 528 | ||||
| Beta | -1.06 | ||||
| Market Capitalization | 6.96 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | (1.8 B) | ||||
| Working Capital | 863.65 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
| Net Asset | 1.04 B |
About Madrigal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Madrigal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Madrigal Pharmaceuticals Piotroski F Score and Madrigal Pharmaceuticals Altman Z Score analysis. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.